Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:4:p3
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 4 (pt 3/22)
Character Range: 187379–190716

for growth promotion containing 50 mg/kg or less of antibiotic substances.
BAMBUTEROL.
BAMETHAN.
BAMIPINE.
BARBITURATES except when separately specified in these Schedules.
BARICITINIB.
BASILIXIMAB.
BAZEDOXIFENE.
BECAPLERMIN.
BECLAMIDE.
BECLOMETASONE except when included in Schedule 2.
BELATACEPT.
BELIMUMAB.
BELUMOSUDIL.
BELZUTIFAN.
BEMEGRIDE.
BENACTYZINE.
BENAZEPRIL.
BENDAMUSTINE.
BENDROFLUAZIDE.
BENETHAMINE PENICILLIN.
BENORYLATE.
BENOXAPROFEN.
BENPERIDOL.
BENRALIZUMAB.
BENSERAZIDE.
BENZATHINE PENICILLIN.
BENZILONIUM.
BENZOCAINE except:
 (a) when included in Schedule 2; or
 (b) in dermal preparations containing 2% or less of total local anaesthetic substances; or
 (c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.
# BENZODIAZEPINE derivatives except when separately specified in these Schedules.
BENZOYL PEROXIDE in preparations for human therapeutic use except:
 (a) when included in Schedule 2; or
 (b) in preparations for external use containing 5% or less of benzoyl peroxide.
BENZPHETAMINE.
BENZTHIAZIDE.
BENZATROPINE.
BENZYDAMINE except:
 (a) when included in Schedule 2; or
 (b) in preparations for dermal use; or
 (c) in divided topical oral preparations containing 3 mg or less of benzydamine; or
 (d) in undivided topical oral preparations containing 0.3% or less of benzydamine in a primary pack containing not more than 50 mL.
BENZYLPENICILLIN.
BEPRIDIL.
BERACTANT.
BESIFLOXACIN.
BETAHISTINE.
BETAMETHASONE.
BETAXOLOL.
BETHANECHOL CHLORIDE.
BETHANIDINE.
BEVACIZUMAB.
BEVANTOLOL.
# BEXAROTENE.
BEZAFIBRATE.
BEZLOTOXUMAB.
BICALUTAMIDE.
BICTEGRAVIR.
BIFONAZOLE except:
 (a) when included in Schedule 2; or
 (b) in preparations for dermal use containing 1% or less of bifonazole for the treatment of the scalp; or
 (c) in preparations for dermal use for the treatment of tinea pedis.
BILASTINE except when included in Schedule 2 or 3.
BIMATOPROST.
BINIMETINIB.
BIPERIDEN.
BISMUTH COMPOUNDS for cosmetic use, except:
 (a) bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5% or less; or
 (b) bismuth oxychloride.
BISMUTH COMPOUNDS for human therapeutic use, except bismuth formic iodide or bismuth subiodide in dusting powders containing 3% or less of bismuth.
BISOPROLOL.
BIVALIRUDIN.
BLEOMYCIN.
BLINATUMOMAB.
BOCEPREVIR.
# BOLANDIOL.
# BOLASTERONE.
# BOLAZINE.
# BOLDENONE (dehydrotestosterone).
# BOLENOL.
# BOLMANTALATE.
BORON, including boric acid and borax, for human therapeutic use except:
 (a) in preparations for internal use containing 6 mg or less of boron per recommended daily dose; or
 (b) in preparations for dermal use containing 0.35% or less of boron, which are not for paediatric or antifungal use; or
 (c) when present as an excipient.
BORTEZOMIB.
# BOSENTAN.
BOSUTINIB.
BOTULINUM TOXINS for human use except when separately specified in these Schedules.
# BPC‑157.
BRENTUXIMAB VEDOTIN.
BRETYLIUM TOSILATE.
BREXPIPRAZOLE.
BRIGATINIB.
BRIMONIDINE except when included in Schedule 2.
BRINZOLAMIDE.
BRIVARACETAM.
# BROMAZEPAM.
BROMIDES, inorganic, for therapeutic use except when separately specified in these Schedules.
BROMOCRIPTINE.
BROMOFORM for therapeutic use.
BROMPHENIRAMINE except when included in Schedule 2 or 3.
BROMVALETONE.
BRUGMANSIA spp.
BUCLIZINE except when included in Schedule 3.
BUDESONIDE except